RSV Vaccines vs. Monoclonal Antibodies

Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Kalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPA
Professor
University of Florida College of Pharmacy

Joshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.
2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-312-H01-P
Initial release date: 11/3/2025
Expiration date: 11/3/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram